RxDoctor Payments Data

Jessica Hendrix, NP

Acute Care · Cincinnati, OHNPI 1083098628

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Boston Scientific at 37.3% of the total. Reporting peaked in 2023 at $2,107 and has fallen 96.7% since, to $70 in 2025. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,175in general payments, 2019–2025

Across 144 payments — averaging $28.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$814
  • AstraZeneca$659
  • Novartis$465
  • Boehringer Ingelheim$192
  • Merck$177
  • plus $311 from 6 others

What the payments were for

  • Travel & lodging$1,92146%
  • Food & beverage$2,25454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,175 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$49,798
Medicare patients
341
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan300$288,477
JardianceEmpagliflozin298$256,546
EliquisApixaban203$161,917
FarxigaDapagliflozin Propanediol23$29,684
XareltoRivaroxaban13$16,708
VerquvoVericiguat18$15,510
Repatha SureclickEvolocumab19$11,463
Torsemide317$5,553
VascepaIcosapent Ethyl16$3,006
Spironolactone436$2,551
Metoprolol Succinate259$2,482
Eplerenone27$1,707
Ezetimibe37$1,706
Bisoprolol Fumarate90$1,291
Amiodarone Hcl101$1,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$465$288,477300 claims
Boehringer IngelheimJardiance$192$256,546298 claims
AstraZenecaFarxiga$659$29,68423 claims
Johnson & JohnsonXarelto$29$16,70813 claims
MerckVerquvo$177$15,51018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.

Other acute care in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →